Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"

2. november 2026 opdateret af: Asmaa Kamel Ahmed Hassan, New Valley University

Retinal arterial macroaneurysm (RAM) is an acquired dilatation of a retinal arteriole that can rupture or leak, causing hemorrhage, exudation, macular edema, and vision loss. No standardized treatment exists, and options range from observation to laser photocoagulation, anti-VEGF therapy, or both.

Laser photocoagulation closes the aneurysm directly and stops leakage. It risks vascular occlusion, temporary worsening of exudate, and scotomas, especially in an actively leaking or edematous macula.

Anti-VEGF therapy reduces vascular permeability and exudation, improving visual acuity and central macular thickness. It does not reliably close the aneurysm itself.

High-dose aflibercept 8 mg has outperformed aflibercept 2 mg in fluid resolution, durability, and dosing interval length in neovascular AMD and diabetic macular edema (PULSAR and PHOTON trials). Its role in RAM-related macular edema, particularly as a pre-laser step to reduce edema and inflammation, has not been studied.

Study rationale: The study will test whether three monthly aflibercept 8 mg loading injections followed by targeted laser to the leaking RAM is a more effective, safer, and more durable sequential strategy than either treatment alone.

Studieoversigt

Detaljeret beskrivelse

Retinal arterial macroaneurysm (RAM) is an acquired focal dilatation of a retinal arteriole, typically within the first three bifurcations, that may rupture or leak to cause hemorrhagic or exudative maculopathy with secondary macular edema and vision loss [1]. Despite its clinical significance, no standardized treatment protocol currently exists; management options range from observation to focal laser photocoagulation, anti-VEGF therapy, or a combination of both [1,2]. Laser photocoagulation directly targets the aneurysmal wall to induce closure and halt leakage, but carries risks of vascular occlusion, transient exudate worsening, and scotoma formation, particularly when applied to an actively leaking or edematous macula [2]. Anti-VEGF agents, by contrast, reduce vascular permeability and reabsorb exudation, improving visual acuity and central macular thickness, but do not reliably induce anatomical closure of the aneurysm itself [1,2].

High-dose intravitreal aflibercept 8 mg has recently demonstrated superior fluid resolution, durability, and extended dosing intervals compared with aflibercept 2 mg in neovascular age-related macular degeneration and diabetic macular edema in the pivotal PULSAR and PHOTON trials [3,4]. However, its role in RAM-associated macular edema, particularly as a pre-laser adjunct to reduce edema and inflammation before aneurysm ablation, remains unexplored.

This gap provides the rationale for the present study: to evaluate whether a loading phase of three monthly aflibercept 8 mg injections, followed by targeted laser photocoagulation of the leaking RAM site, offers a more effective, safer, and durable sequential treatment strategy for RAM-related macular edema than either modality alone

Undersøgelsestype

Observationel

Tilmelding (Anslået)

15

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

15 patients who were diagnosed with RAM and fulfilling study certria

Beskrivelse

1-1-Age ≥ 18 years, of either sex 2-Clinical and imaging-confirmed diagnosis of retinal arterial macroaneurysm 3-Presence of macular edema secondary to RAM involving the central subfield, with central macular thickness (CMT) > 300 µm on OCT.

4-Treatment-naïve eyes (no prior anti-VEGF injection or laser therapy for the current RAM episode).

5-Willingness and ability to comply with the monthly injection schedule and follow-up visits.

6-Signed informed consent 5-All patients were diagnosed with RAM not associated with comorbidity, such as diabetes, glaucoma

Exclusion criteria:

  1. RAM leakage site inaccessible to laser photocoagulation (e.g., juxtafoveal or subfoveal location precluding safe laser application).
  2. Significant vitreous hemorrhage precluding adequate fundus visualization or laser delivery.
  3. Known hypersensitivity to aflibercept or any component of its formulation. 4. Pregnancy or breastfeeding.

5-Systemic conditions precluding safe intravitreal injection (e.g., recent stroke or myocardial infarction within 3 months, uncontrolled thromboembolic disease).

6-Media opacity precluding adequate OCT/FFA imaging or laser treatment (e.g., dense cataract, corneal opacity).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in central macular thickness (CMT), measured by spectral-domain optical coherence tomography (SD-OCT), from baseline to the final follow-up visit following sequential aflibercept 8 mg loading doses and laser photocoagulation
Tidsramme: 5 mnoths

Spectral-domain optical coherence tomography (SD-OCT) Heidelberg machine: central macular thickness Best-corrected visual acuity (BCVA) is measured using the ETDRS/log MAR chart.

5 mnoths

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. februar 2027

Studieafslutning (Anslået)

1. marts 2027

Datoer for studieregistrering

Først indsendt

28. oktober 2026

Først indsendt, der opfyldte QC-kriterier

2. november 2026

Først opslået (Faktiske)

6. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner